Changes to the CDC Adult Immunization Schedule for 2020
Note: “Those with a history of Guillain–Barré syndrome within 6 weeks of a previous dose of influenza vaccine generally should not be vaccinated, unless vaccination benefits outweigh risks for those at higher risk for severe complications from influenza.”
Note: Any person who is not at risk for hepatitis A virus infection but wants protection against it may be vaccinated
Catch-up HPV vaccination (not adequately vaccinated previously)
Public health benefit of HPV vaccinations for adults in this age range is minimal, yet some persons who are not adequately vaccinated might benefit. HPV vaccination does not need to be discussed with most adults older than 26 years of age, but clinicians can consider discussing HPV vaccination with persons who are most likely to benefit. HPV vaccines are not licensed for use in adults older than age 45 years.
Recommended Adult Immunization Schedule, United States, 2020
In October 2017, the FDA approved and ACIP recommended a Shingrix (RZV) vaccine for adults ≥50 years of age. Zostavax (ZVL) is no longer available for use in the United States, as of November 18, 2020.
Shingrix is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years
CDC MMWR: Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR (cdc.gov)
CDC: Shingles (Herpes Zoster) Vaccination Information for Healthcare Providers
FDA: SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted)
CDC Epidemiology and Prevention of Vaccine-Preventable Diseases; The Pink Book: Course Textbook – 13th Edition (2015)
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study
Please log in to ObGFirst to access the 2T US Atlas